The clinical phenotype of myelofibrosis (MF) is recognized either de novo (primary) or in the
setting of polycythemia vera (post‐PV) or essential thrombocythemia (post‐ET) …

Among 826 patients with primary myelofibrosis (PMF) and analysable metaphases on
cytogenetic studies, 352 (42· 6%) had abnormal karyotype, of which 240 (68· 2%) were sole …

Abstract Objectives: The International Prognostic Scoring System (IPSS) for primary
myelofibrosis (PMF) is based on five independent predictors of inferior survival: age> 65 yr …

Polycythemia vera (PV) is a chronic myeloproliferative disease characterized by an increase
of total red cell volume; in 10% to 15% of cases, bone marrow fibrosis complicates the …

The prognostic significance of cytogenetic abnormalities was determined in 106 patients
with well‐characterized idiopathic myelofibrosis who were successfully karyotyped at …

We have previously identified sole+ 9, 13q-or 20q-, as 'favorable'and sole+ 8 or complex
karyotype as 'unfavorable'cytogenetic abnormalities in primary myelofibrosis (PMF). In this …

Objectives: To compare the mutational profiles of patients with primary myelofibrosis (PMF),
polycythemia vera (PV), and essential thrombocytosis (ET). Methods: Next-generation …

Cytogenetic abnormalities were often observed in primary myelofibrosis patients. The
presence of specific cytogenetic abnormalities, such as sole abnormalities of chromosome …

Although cytogenetic abnormalities are important prognostic factors in myeloid
malignancies, they are not included in current prognostic scores for primary myelofibrosis …

Simple Summary Myelofibrosis is an aggressive bone marrow cancer whose clinical
presentation can be extremely heterogenous. Two distinct phenotypes, myeloproliferative …